ATG-037-001
29 Nov 2022
ATG-037-001
NCT05205109
A Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Antengene Therapeutics Limited
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 Years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2022-12-31 |
Anticipated End Date | 2024-08-30 |
Hospital | Southern Oncology Clinical Research Unit |
---|---|
Clinical Trial Coordinator | Meggan O'Riley |
Meggan.ORiley@socru.org.au | |
Phone | 0491 679 039 |
Principal Investigator | Dr Ganessan Kichenadasse |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs